Literature DB >> 11928991

Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics.

Jason T Newman1, Sonja R Surman, Jeffrey M Riggs, Chris T Hansen, Peter L Collins, Brian R Murphy, Mario H Skiadopoulos.   

Abstract

A complete consensus sequence was determined for the genomic RNA of human parainfluenza virus type 1 (HPIV1) strain Washington/20993/1964 (HPIV1 WASH/64), a clinical isolate that previously was shown to be virulent in adults. The sequence exhibited a high degree of relatedness to both Sendai virus, a PIV1 virus recovered from mice, and human PIV3 (HPIV3) with regard to cis-acting regulatory regions and protein-coding sequences. This consensus sequence was used to generate a full-length antigenomic cDNA and to recover a recombinant wild-type HPIV1 (rHPIV1). Interestingly, the rHPIV1 could be rescued from full-length antigenomic rHPIV1 cDNA using HPIV3 support plasmids, HPIV1 support plasmids, or a mixture thereof. The replication of rHPIV1 in vitro and in the respiratory tract of hamsters was similar to that of its biologically derived parent virus. The similar biological properties of rHPIV1 and HPIV1 WASH/64 in vitro and in vivo, together with the previous demonstration of the virulence of this specific isolate in humans, authenticates the rHPIV1 sequence as that of a wild-type virus. This rHPIV1 can now be used to study the biological properties of HPIV1 and as a substrate to introduce attenuating mutations for the generation of live-attenuated HPIV1 vaccine candidates.

Entities:  

Mesh:

Year:  2002        PMID: 11928991     DOI: 10.1023/a:1014042221888

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  67 in total

1.  Dissection of individual functions of the Sendai virus phosphoprotein in transcription.

Authors:  M C Bowman; S Smallwood; S A Moyer
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Sequence of the hemagglutinin-neuraminidase gene of human parainfluenza virus type 1.

Authors:  Y Matsuoka; R Ray; R W Compans
Journal:  Virus Res       Date:  1990-04       Impact factor: 3.303

3.  The activity of Sendai virus genomic and antigenomic promoters requires a second element past the leader template regions: a motif (GNNNNN)3 is essential for replication.

Authors:  C Tapparel; D Maurice; L Roux
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

4.  Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells.

Authors:  L S Wyatt; B Moss; S Rozenblatt
Journal:  Virology       Date:  1995-06-20       Impact factor: 3.616

5.  Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development.

Authors:  P L Collins; M G Hill; E Camargo; H Grosfeld; R M Chanock; B R Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

6.  Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts.

Authors:  M H Skiadopoulos; T Tao; S R Surman; P L Collins; B R Murphy
Journal:  Vaccine       Date:  1999-10-14       Impact factor: 3.641

7.  Ribosomal frameshifting during translation of measles virus P protein mRNA is capable of directing synthesis of a unique protein.

Authors:  P Liston; D J Briedis
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants.

Authors:  R A Karron; M Makhene; K Gay; M H Wilson; M L Clements; B R Murphy
Journal:  Pediatr Infect Dis J       Date:  1996-08       Impact factor: 2.129

9.  Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine.

Authors:  M H Skiadopoulos; S Surman; J M Tatem; M Paschalis; S L Wu; S A Udem; A P Durbin; P L Collins; B R Murphy
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

10.  The parainfluenza virus type 1 P/C gene uses a very efficient GUG codon to start its C' protein.

Authors:  R Boeck; J Curran; Y Matsuoka; R Compans; D Kolakofsky
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

View more
  30 in total

Review 1.  Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics.

Authors:  Brian R Murphy; Peter L Collins
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

2.  Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro.

Authors:  Josephine M McAuliffe; Sonja R Surman; Jason T Newman; Jeffrey M Riggs; Peter L Collins; Brian R Murphy; Mario H Skiadopoulos
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

Review 3.  Nonsegmented negative-strand viruses as vaccine vectors.

Authors:  Alexander Bukreyev; Mario H Skiadopoulos; Brian R Murphy; Peter L Collins
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

4.  Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates.

Authors:  Anne Schaap-Nutt; Caraline Higgins; Emerito Amaro-Carambot; Sheila M Nolan; Christopher D'Angelo; Brian R Murphy; Peter L Collins; Alexander C Schmidt
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

5.  Complete genome sequence of avian paramyxovirus type 3 reveals an unusually long trailer region.

Authors:  Sachin Kumar; Baibaswata Nayak; Peter L Collins; Siba K Samal
Journal:  Virus Res       Date:  2008-08-15       Impact factor: 3.303

6.  Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo.

Authors:  Quynh N Pham; Stéphane Biacchesi; Mario H Skiadopoulos; Brian R Murphy; Peter L Collins; Ursula J Buchholz
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

7.  The genome length of human parainfluenza virus type 2 follows the rule of six, and recombinant viruses recovered from non-polyhexameric-length antigenomic cDNAs contain a biased distribution of correcting mutations.

Authors:  Mario H Skiadopoulos; Leatrice Vogel; Jeffrey M Riggs; Sonja R Surman; Peter L Collins; Brian R Murphy
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

8.  The C proteins of human parainfluenza virus type 1 (HPIV1) control the transcription of a broad array of cellular genes that would otherwise respond to HPIV1 infection.

Authors:  Jim B Boonyaratanakornkit; Emmalene J Bartlett; Emerito Amaro-Carambot; Peter L Collins; Brian R Murphy; Alexander C Schmidt
Journal:  J Virol       Date:  2008-12-03       Impact factor: 5.103

9.  The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness.

Authors:  Mario H Skiadopoulos; Stéphane Biacchesi; Ursula J Buchholz; Jeffrey M Riggs; Sonja R Surman; Emerito Amaro-Carambot; Josephine M McAuliffe; William R Elkins; Marisa St Claire; Peter L Collins; Brian R Murphy
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in non-human primates.

Authors:  Anne Schaap-Nutt; Christopher D'Angelo; Margaret A Scull; Emerito Amaro-Carambot; Machiko Nishio; Raymond J Pickles; Peter L Collins; Brian R Murphy; Alexander C Schmidt
Journal:  Virology       Date:  2009-12-07       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.